Trans-Center Small Molecule Screening Laboratory

RCE中小分子筛选核心的目标是支持生物防御相关的 针对开发能够干扰肿瘤的新型治疗剂的研究 生物武器的活动。一个完全自动化的设施，能够执行一些小的 分子筛，将建立。核心将占据哈佛医疗中心新改建的空间 学校，它将配备最先进的机器人设备，并将组装一些 合成化合物文库。这些资源，加上训练有素的工作人员的专门知识， 提供给RCE内部的个别研究者，以及有价值的研究者， 新英格兰以外的生物防御相关项目。该核心将与研究所密切互动， 化学和细胞生物学在哈佛，进一步扩大核心的能力。根据专业知识， 核心的工作人员，许多不同的，高通量筛选平台将得到支持，包括 全细菌测定、蛋白酶测定、蛋白质-蛋白质或蛋白质-配体相互作用测定，以及 使用培养的哺乳动物细胞的各种基于细胞的测定。核心小组将协助调查人员 使用计算机化数据库对化合物进行后续分析，并将有助于开发更精确的 卡位核心计划的长远目标，是推动小说筛选的发展， 以满足不断变化的生物防御需求。此外，它将作为测试的集中资源 替代的天然或合成化合物文库以及促进RCE之间的相互作用 研究人员和药物化学家在开发先导化合物的治疗产品。 有前途的化合物的进一步开发将与MAID协商评估， 工业伙伴和NERCE科学指导委员会。

The objective of the Small Molecule Screening Core within the RCE is to support biodefense-related research directed towards the development of new classes of therapeutic agents capable of interfering with the activities of biological weapons. A fully automated facility, capable of executing a number of small molecule screens, will be established. The Core will occupy newly remodeled space at Harvard Medical School, it will be equipped with the state of the art robotic equipment, and will assemble a number of synthetic compound libraries. These resources, together with the expertise of highly trained staff will be made available to individual investigators within the RCE, as well as to investigators with meritorious, biodefense related projects outside of the New England. The core will interact closely with the Institute of Chemistry and Cell Biology at Harvard, further expanding the core's capabilities. Based on the expertise of the Core's staff, a number of diverse, high-throughput screening platforms will be supported, including whole bacterial assays, protein enzyme assays, protein-protein or protein-ligand interaction assays, and a variety of cell-based assays using cultured mammalian cells. The Core will assist the investigators in follow-up analysis of compounds using computerized databases, and will help in the development of moreprecise screens. The long-term objectives of the Core are to promote the development of novel screening platforms to meet changing biodefense needs. Moreover, it will serve as a centralized resource for testing alternative natural or synthetic compound libraries as well as promote interactions between RCE investigators and medicinal chemists in the development of lead compounds to therapeutic products. Further development of promising compounds will be evaluated in consultation with MAID, interested industrial partners, and the NERCE Scientific Steering Committee.